GlassScriptPhysician profile
Rita Greige
NPI 1366088726
$6,080.03
in general payments reported to CMS, 2019-2025
29 companies · $3,524 in 2025
The $3,524 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $721 · 2022: $635 · 2023: $299 · 2024: $901 · 2025: $3,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,269 · Education: $306 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,268.87 |
| Education | $305.60 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.31 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $896.38 | 2021-2025 | Xifaxan |
| Harmony Biosciences LLC | $577.82 | 2023-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $465.31 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $296.80 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Jazz Pharmaceuticals INC. | $289.52 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $240.62 | 2025 | Tremfya |
| Ardelyx, INC. | $238.04 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $197.98 | 2025 | Dupixent |
| Axsome Therapeutics, INC. | $192.97 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $186.52 | 2024 | Inspire |
| Madrigal Pharmaceuticals | $181.05 | 2025 | Rezdiffra |
| Pfizer INC. | $157.04 | 2021-2025 | |
| Gilead Sciences, INC. | $153.27 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $126.07 | 2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $120.81 | 2021-2025 | Sucraid |
| Idorsia Pharmaceuticals US INC | $103.63 | 2023-2024 | Quviviq |
| Resmed Corp | $96.69 | 2024 | |
| Aimmune Therapeutics, INC. | $71.58 | 2025 | Zenpep |
| Evoke Pharma, INC. | $64.93 | 2021-2025 | |
| 3b Medical, INC. | $41.31 | 2023 | Luna |
| Ironwood Pharmaceuticals, INC | $39.51 | 2021 | |
| Glaxosmithkline, LLC. | $37.89 | 2023 | Nucala |
| Daiichi Sankyo INC. | $31.33 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.14 | 2024 | Horizant |
| Lilly USA, LLC | $15.74 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $15.51 | 2022 | |
| Intercept Pharmaceuticals, INC. | $14.34 | 2021 | |
| Celgene Corporation | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Greige listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.